CLINICAL TRIAL OF THROMBOLYSIS IN MYOCARDIAL INFARCATION

心肌梗塞溶栓的临床试验

• 批准号: 3660128
• 负责人: ALLAN M ROSS
• 金额: $ 17.7万
• 依托单位: GEORGE WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-06-30 至 1988-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3660128
• 关键词: cardiotonic agents; cooperative study; coronary vasodilator; drug administration routes; drug adverse effect; fibrinolytic agents; fibrinolytic therapy; heart imaging /visualization /scanning; heart motion; human subject; human therapy evaluation; intracardiac volume; myocardial infarct sizing; myocardial infarction; nitroglycerin; radionuclide diagnosis

Assess the efficacy of a thrombolytic agent in reducing infarct size and thereby improving ventricular function and subsequent morbidity and mortality. The primary endpoint will be total mortality during the follow up period. Secondary endpoints include determination of the: effect of thrombolytic therapy on left ventricular ejection fraction;proportion of patients suspected of having myocardial infarction with complete versus incomplete occlusion of the infarct related artery; time limits for successful reperfusion including differences according to the route of administration; and frequency and severity of adverse effects of intracoronary and intravenous administration of thrombolytic agents in patients with acute infarction.

评估溶栓药物在减少梗死面积方面的疗效， 从而改善心室功能和随后的发病率， mortality. 主要终点将是以下期间的总死亡率 上时期。 次要终点包括确定： 溶栓治疗对左室射血分数的影响; 疑似心肌梗死的患者， 梗死相关动脉的不完全闭塞; 成功的再灌注，包括根据途径的差异 给药的频率和严重程度; 冠状动脉内和静脉内给药血栓溶解剂 急性脑梗死患者。